# US 2023/0414717 A1 · Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414717 A1
- Document ID: US20230414717A1
- Status: Published application
- Kind: A1
- Application number: 18/129,133
- Filed: 2023-03-31
- Published: 2023-12-28
- Earliest claimed: 2017-09-08
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Edgar Davidson CHARLES, III; Rose C. CHRISTIAN; Yi LUO
- Web page: https://patentgrep.com/patent/US20230414717A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.

## Claims

### Claim 1

A method for treating a patient having Nonalcoholic Steatohepatitis (NASH) comprising: (a) determining the serum Pro-C3 level in a blood sample from the patient and (b) administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH, if the serum Pro-C3 level is greater than 10 ng/ML.

### Claim at position 2

-4. (canceled)

### Claim 5

A method for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.

### Claim 6 (depends on 1)

The method of claim 1, wherein the serum Pro-C3 level prior to administration to the patient of a modified Fibroblast growth factor 21 (FGF-21) is greater than about 11 ng/ML, 12 ng/ML, 13 ng/ML, 14 ng/ML, 15 ng/ML, 16 ng/ML, 17 ng/ML, 18 ng/ML, 19 ng/ML, 20 ng/ML, 21 ng/ML, 22 ng/ML, 23 ng/ML, 24 ng/ML, or 25 ng/ML.

### Claim 7 (depends on 6)

The method of claim 6, wherein the serum Pro-C3 level is greater than about 15 ng/ML.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Pro-C3 level or levels are measured by an FDA-approved test.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Pro-C3 level or levels are measured by using an immunoassay, immunochemistry, immunohistochemistry assay, nucleoprobe assay, in situ hybridization, fluorescent RNA probes, RT-PCR, microarray transcription assay, or RNA transcription assay.

### Claim 10 (depends on 9)

The method of claim 9, wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RIA).

### Claim 11 (depends on 1)

The method of claim 1, wherein the modified FGF-21 comprises the polypeptide of SEQ ID NO:1, except that an amino acid in the polypeptide is substituted by a non-naturally encoded amino acid, wherein: (a) said non-naturally encoded amino acid is at a position corresponding to residue 108 of SEQ ID NO:1; and (b) said non-naturally encoded amino acid comprises para-acetyl phenylalanine linked to a polymer comprising a poly(ethylene glycol).

### Claim 12 (depends on 1)

The method of claim 1, wherein the modified FGF-21 comprises the polypeptide of SEQ ID NO:1 except that the amino acid at position 108 of SEQ ID NO:1 is substituted by a non-naturally encoded amino acid, wherein: (a) said non-naturally encoded amino acid comprises para-acetyl phenylalanine, and (b) said non-naturally encoded amino acid is linked to a polymer comprising a poly(ethylene glycol) having an average molecular weight of about 30 kDa.

### Claim 13 (depends on 11)

The method of claim 11, wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa.

### Claim 14 (depends on 11)

The method of claim 11, wherein said non-naturally encoded amino acid is linked to said polymer through an oxime linkage.

### Claim 15 (depends on 1)

The method of claim 1, wherein the modified FGF-21 comprises SEQ ID NO:2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the modified FGF-21 comprises a poly(ethylene glycol) having an average molecular weight of about 30 kDa.

### Claim 17 (depends on 16)

The method of claim 16, wherein the poly(ethylene glycol) is linked to para-acetyl phenylalanine.

### Claim 18 (depends on 1)

The method of claim 1, wherein the modified FGF-21 is administered at a once weekly dose of 20 mg or a once daily dose of 10 mg.

### Claim 19 (depends on 1)

The method of claim 1, comprising administration of a second therapeutic agent.

### Claim 20 (depends on 1)

The method of claim 1, wherein the treatment:
(a) results in a decrease in serum Pro-C3 levels in the patient;
(b) produces a shift toward normal serum levels of Pro-C3 in the patient;
(c) results in a reduction in liver stiffness in the patient compared to the patient's liver stiffness prior to treatment, wherein liver stiffness is assessed by magnetic resonance elastography (MRE); and/or
(d) results in a reduction in hepatic fat fraction in the patient compared to the patient's hepatic fat fraction prior to treatment, wherein hepatic fat fraction is as assessed by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF).

### Claim at position 19

-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the treatment produces at least one therapeutic effect in the patient selected from the group consisting of a reduction or cessation in fatigue, malaise, weight loss, and/or right upper quadrant abdominal discomfort.

### Claim at position 21

-30. (canceled)
